Latest News-CSTONE PHARMACEUTICALS Mediaroom_Page

CStone presents updated results of a registrational study of sugemalimab in patients with stage III NSCLC via oral presentation at WCLC 2022

* GEMSTONE-301 study result was presented at IASLC 2022 World Conference on Lung Cancer. In addit...

2022-08-08 08:08 2468

CStone Announces the NDA Approval of GAVRETO® (pralsetinib) for the Treatment of RET Fusion-Positive treatment-naïve (first-line) and pretreated Non-Small Cell Lung Cancer (NSCLC) in Hong Kong, China

* GAVRETO is the first highly selective rearranged during transfection (RET) inhibitor approved i...

2022-07-15 08:02 3679

CStone presents pre-specified overall survival data of sugemalimab for first-line treatment of stage IV non-small cell lung cancer at ASCO 2022

* Sugemalimab is the world's first PD-L1 monoclonal antibody to show the statistically significan...

2022-06-07 08:02 3025

CStone and Pfizer announce NMPA approval of sugemalimab in patients with unresectable stage III non-small cell lung cancer

* The National Medical Products Administration approved sugemalimab for the treatment of patients...

2022-06-06 13:15 2848

CStone and Pfizer announce NMPA approval of sugemalimab in patients with unresectable stage III non-small cell lung cancer

* The National Medical Products Administration approved sugemalimab for the treatment of patients...

2022-06-06 12:23 2295

CStone presents updated results of anti-PD-1 antibody nofazinlimab in combination with lenvatinib as first-line treatment in patients with unresectable hepatocellular carcinoma (HCC) at ASCO 2022

* Nofazinlimab in combination with lenvatinib as first-line treatment for unresectable hepatocell...

2022-06-05 08:02 4909

CStone presents clinical results of sugemalimab in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma via an oral abstract session at ASCO 2022

* GEMSTONE-201 is the largest registrational clinical study of an anti-PD-(L)1 antibody reported ...

2022-06-04 08:02 7205

CStone Pharmaceuticals Reports 2021 Annual Results and Recent Business Highlights

SUZHOU, China, June 1, 2022 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leadin...

2022-06-01 00:35 5831

CStone announces final PFS analysis of a registrational study of sugemalimab in patients with stage III NSCLC further demonstrates its robust efficacy and significant clinical benefits shown in interim analysis

* Sugemalimab is the world's first anti-PD-(L)1 monoclonal antibody to significantly improve prog...

2022-05-17 08:02 2988

CStone to present the latest clinical results of anti-PD-L1 antibody sugemalimab and anti-PD-1 antibody nofazinlimab at ASCO 2022

* Results from GEMSTONE-201 study of sugemalimab, the first successful registrational clinical st...

2022-04-28 08:00 2532

CStone Announces Results From Phase 3 AGILE Data of TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine for Patients with Previously Untreated IDH1-mutated Acute Myeloid Leukemia Published in the New England Journal of Medicine

* Results from the trial present a significant advancement for patients dealing with previously u...

2022-04-22 08:02 3402

CStone Announces Presentation of Preclinical data on a Multi-Specific Antibody-based Therapeutic Candidate CS2006/NM21-1480 at the American Association for Cancer Research (AACR) Annual Meeting 2022

* Results from pharmacokinetic/pharmacodynamic modeling demonstrated that binding affinity optimi...

2022-04-13 08:02 2181

CStone announces first patient enrollment in the U.S. in the Phase 1 clinical trial of CS5001, a potential global best-in-class ROR1-targeting ADC

* Commencement of the first-in-human clinical trial of CS5001 marks another key milestone for CSt...

2022-03-31 08:02 3153

CStone Pharmaceuticals Announces the Acceptance of New Drug Application (NDA) for Pralsetinib for the Treatment of RET Fusion-Positive Non-Small Cell Lung Cancer (NSCLC) in Hong Kong, China

SUZHOU, China, March 18, 2022 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a lead...

2022-03-18 10:35 2955

CStone announced the global multi-regional registration trial of anti-PD-1 antibody nofazinlimab in combination with lenvatinib as first-line treatment for patients with advanced hepatocellular carcinoma successfully reached the prespecified enrollment target

SUZHOU, China, March 18, 2022 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a lead...

2022-03-18 08:37 3271

CStone announces the NMPA approval of GAVRETO (pralsetinib) for the treatment of Advanced or Metastatic RET-mutant medullary thyroid cancer and RET fusion-positive thyroid cancer

* GAVRETO is the first and only selective rearranged during transfection (RET) inhibitor approved...

2022-03-14 08:05 3064

CStone Pharmaceuticals Announces the Acceptance of New Drug Application (NDA) for Pralsetinib for the Treatment of RET Fusion-Positive Non-Small Cell Lung Cancer (NSCLC) and RET-Altered Thyroid Cancers in Taiwan, China

SUZHOU, China, Feb. 17, 2022 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leadi...

2022-02-17 09:19 4189

CStone announced new drug approval of China's first IDH1 inhibitor TIBSOVO® (ivosidenib tablets) as a new precision therapy for patients with acute myeloid leukemia

* TIBSOVO®, a first-in-class drug, is approved for adult patients with relapsed/refractory acute ...

2022-02-09 11:53 3644

CStone announces the GEMSTONE-302 study of sugemalimab met the endpoint of overall survival in the first-line treatment of metastatic non-small cell lung cancer patients

* Sugemalimab is the world's first PD-L1 monoclonal antibody that when administered along with ch...

2022-01-19 08:05 3137

CStone announced two key phase 3 registrational clinical trials of sugemalimab completed patient enrollment

* Both trials investigate first-line treatment with sugemalimab combined with chemotherapy in pat...

2022-01-18 08:00 3780